

10598841

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPplus and USPAT databases updated with IPC

10598841

reclassification data
NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records
NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations
NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:30:34 ON 05 JUL 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:30:50 ON 05 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JUL 2008 HIGHEST RN 1032821-09-2

DICTIONARY FILE UPDATES: 4 JUL 2008 HIGHEST RN 1032821-09-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

10598841

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10598841.str



chain nodes :
10 11 13 16 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-16 3-13 4-11 8-10 9-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-16 3-4 3-13 4-5 4-11 5-6 5-7 6-9 7-8 8-10 9-17
exact bonds :
8-9
isolated ring systems :
containing 1 :

G1:H,CH3,X

G2:Cy,Ak


G4:H,CH3,X,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

10598841

=> d
L1 HAS NO ANSWERS
L1 STR



G1 H, Me, X
G2 Cy, Ak
G3
G4 H, Me, X, O

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 15:31:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1029 TO ITERATE

100.0% PROCESSED 1029 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 18656 TO 22504
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 15:31:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20098 TO ITERATE

100.0% PROCESSED 20098 ITERATIONS 71 ANSWERS
SEARCH TIME: 00.00.01

L3 71 SEA SSS FUL L1

=> fil cal
'CAL' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue

10598841

=> fil capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

189.28

189.49

FILE 'CAPLUS' ENTERED AT 15:32:55 ON 05 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Jul 2008 VOL 149 ISS 2

FILE LAST UPDATED: 4 Jul 2008 (20080704/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3

L5 5 L3

=> d l5 ibib hitstr abs 1-5

10598841


L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1147232 CAPLUS
DOCUMENT NUMBER: 145:471529
TITLE: Preparation of imidazo[1,2-a]pyridine derivatives
useful as peptide deformylase (PDF) inhibitors
INVENTOR(S): Thormann, Michael
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 37pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006114261	A1	20061102	WO 2006-EP3765	20060424
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006239546	A1	20061102	AU 2006-239546	20060424
CA 2606251	A1	20061102	CA 2006-2606251	20060424
EP 1877407	A1	20080116	EP 2006-742662	20060424
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2007DN07463	A	20071109	IN 2007-DN7463	20070927
KR 2008002866	A	20080104	KR 2007-724436	20071024
MX 200713237	A	20080124	MX 2007-13237	20071024
CN 101166740	A	20080423	CN 2006-80014036	20071025
PRIORITY APPLN. INFO.:			DE 2005-102005019180A	20050425
			WO 2006-EP3765	W 20060424


OTHER SOURCE(S): MARPAT 145:471529

IT 913707-62-7P, N-Hydroxy-2-[(7-methylimidazo[1,2-a]pyridin-2-yl)amino]-3-phenylpropionamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-a]pyridine derivs. useful as peptide deformylase (PDF) inhibitors)
RN 913707-62-7 CAPLUS
CN Benzenepropanamide, N-hydroxy- α -[(7-methylimidazo[1,2-a]pyridin-2-yl)amino]- (CA INDEX NAME)

10598841



GI



AB Title compds. represented by the formula I [wherein R₁-R₄ = independently H, halo, OH, amino, etc.; R₅ = H, halo, (hetero)aryl, etc.; R₆, R₇ = H, (cyclo)alkyl, (hetero)aryl, etc.; X = -CS-NHOH, -CO-CH₂OH, -CHOH-CHO, etc.; and pharmaceutically acceptable salts, solvates or hydrates thereof] were prepared as peptide deformylase (PDF) inhibitors. The general procedure for preparation of I was described, 328 compds. were prepared I were investigated for their activity as PDF inhibitors with IC₅₀ values ranging between 1 nmol and 50 μ mol. Thus, I and their pharmaceutical compns. are useful as new antibiotics.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1042069 CAPLUS
 DOCUMENT NUMBER: 143:347170
 TITLE: Preparation of imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
 INVENTOR(S): Sciotti, Richard John; Starr, Jeremy Tyson; Richardson, Christopher; Rewcastle, Gordon William; Palmer, Brian Desmond; Sutherland, Hamish Scott; Spicer, Julie Ann; Chen, Huifen
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089763	A1	20050929	WO 2005-IB596	20050307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AW, BH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2559229	A1	20050929	CA 2005-2559229	20050307
EP 1737459	A1	20070103	EP 2005-708696	20050307
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
BR 2005007653	A	20070710	BR 2005-7653	20050307
JP 2007529496	T	20071025	JP 2007-503429	20050307
US 20070191394	A1	20070816	US 2006-598841	20060913
MX 2006PA10683	A	20061116	MX 2006-PA10683	20060918
PRIORITY APPLN. INFO.:			US 2004-554510P	P 20040319
			US 2004-630777P	P 20041123
			WO 2005-IB596	W 20050307


OTHER SOURCE(S): CASREACT 143:347170; MARPAT 143:347170

IT 865604-19-9P, 1-Ethyl-3-[7-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-56-4P, 4-[2-(3-Ethylureido)imidazo[1,2-a]pyridin-7-yl]-3,5-dimethylpyrazole-1-carboxylic acid tert-butyl ester 865604-60-0P, 2-(3-Ethylureido)imidazo[1,2-a]pyridine-7-carboxylic acid methyl ester 865604-64-4P, 2-(3-Ethylureido)imidazo[1,2-a]pyridine-7-carboxamide 865604-86-0P, 2-(3-Ethylureido)imidazo[1,2-a]pyridine-7-carboxylic acid 865605-06-7P, [4-[2-(3-Ethylureido)imidazo[1,2-a]pyridin-7-yl]pyridin-2-yl]carbamic acid tert-butyl ester
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (antibacterial agent; preparation of imidazopyridines and imidazopyrimidines as antibacterials)

10598841


RN 865604-19-9 CAPLUS

CN Urea, N-ethyl-N'-[7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)




RN 865604-56-4 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 4-[2-[[(ethylamino)carbonyl]amino]imidazo[1,2-a]pyridin-7-yl]-3,5-dimethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865604-60-0 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 2-[[(ethylamino)carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 865604-64-4 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 2-[[(ethylamino)carbonyl]amino]- (CA INDEX NAME)



RN 865604-86-0 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 2-[[(ethylamino)carbonyl]amino]- (CA INDEX NAME)

10598841



RN 865605-06-7 CAPLUS

CN Carbamic acid, [4-[2-[[[(ethylamino)carbonyl]amino]imidazo[1,2-a]pyridin-7-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 865604-18-8P, [7-(Pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]carbamic acid ethyl ester 865604-21-3P, [7-(2-Dimethylaminopyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]carbamic acid ethyl ester 865604-22-4P, 1-[7-(2-Dimethylaminopyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865604-23-5P, [7-(6-Methoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]carbamic acid ethyl ester 865604-24-6P, 1-Ethyl-3-[7-(6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-25-7P, 1-Ethyl-3-[7-(2-methoxypyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-28-0P, 1-Ethyl-3-[7-[6-[2-(morpholin-4-yl)ethoxy]pyridin-3-yl]imidazo[1,2-a]pyridin-2-yl]urea 865604-36-0P, 1-Ethyl-3-[5-hydroxymethyl-7-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-37-1P, 1-Ethyl-3-[5-formyl-7-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-38-2P, 2-(3-Ethylureido)-7-(pyridin-3-yl)imidazo[1,2-a]pyridine-5-carboxylic acid methyl ester 865604-50-8P, 1-Ethyl-3-[7-(pyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-51-9P, 1-[7-(3,5-Dimethylisoxazol-4-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865604-52-0P, 1-[7-(1-Benzyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865604-53-1P, 1-Ethyl-3-[7-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]imidazo[1,2-a]pyridin-2-yl]urea 865604-54-2P, 1-Ethyl-3-[7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-55-3P, 1-[7-(2,4-Dimethoxypyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865604-57-5P, 1-Ethyl-3-[7-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-58-6P, 1-[3-Chloro-7-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865604-59-7P, 1-[3-Chloro-7-(2-dimethylaminopyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865604-65-5P, 1-Ethyl-3-[7-(5-methyl-2H-[1,2,4]triazol-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-67-7P, 1-[7-(1,5-Dimethyl-1H-[1,2,4]triazol-3-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865604-68-8P, 1-[7-(2,5-Dimethyl-2H-[1,2,4]triazol-3-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865604-69-9P, 1-Ethyl-3-[7-(5-methyl-[1,2,4]oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-76-8P, 1-Ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-87-1P,

1-[7-(3,5-Dimethyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea
 865604-88-2P, 1-Ethyl-3-[7-[(piperidin-1-yl)carbonyl]imidazo[1,2-a]pyridin-2-yl]urea 865604-89-3P, 1-Cyclopropyl-3-[7-(pyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-92-8P,
 1-Cyclopropylmethyl-3-[7-(pyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]urea
 865604-93-9P, 1-Propyl-3-[7-(pyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-94-0P, 1-Isopropyl-3-[7-(pyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-96-2P,
 1-[7-(Pyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]-3-(2,2,2-trifluoroethyl)urea 865604-98-4P, 1-(2-Methoxyethyl)-3-[7-(pyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]urea 865604-99-5P,
 1-Cyclobutyl-3-[7-(pyrimidin-5-yl)imidazo[1,2-a]pyridin-2-yl]urea
 865605-00-1P, 1-[7-(6-Aminopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea 865605-01-2P, 1-(7-Acetyl)imidazo[1,2-a]pyridin-2-yl)-3-ethylurea 865605-04-5P, 1-Ethyl-3-[7-(5-methyl-[1,3,4]oxadiazol-2-yl)imidazo[1,2-a]pyridin-2-yl]urea 865605-07-8P
 865605-11-4P, 1-Ethyl-3-[7-([1,2,3]thiadiazol-4-yl)imidazo[1,2-a]pyridin-2-yl]urea 865605-13-6P, 1-Ethyl-3-[7-(5-isopropyl-[1,2,4]oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865605-16-9P
 , 1-Ethyl-3-[7-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865605-17-0P 865605-18-1P,
 1-Ethyl-3-[7-[(morpholin-4-yl)carbonyl]imidazo[1,2-a]pyridin-2-yl]urea
 865605-19-2P, 1-Ethyl-3-[7-(2-methoxypyridin-4-yl)imidazo[1,2-a]pyridin-2-yl]urea 865605-20-5P, 1-Ethyl-3-[5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea
 865605-21-6P, 1-Ethyl-3-[7-(6-fluoropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865605-22-7P, 1-Ethyl-3-[7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea
 865605-23-8P, 1-Ethyl-3-[7-(6-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea 865605-24-9P, 1-Ethyl-3-[7-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyridin-2-yl]urea
 865605-25-0P, 7-(2-Dimethylaminopyrimidin-5-yl)-2-(3-ethylureido)imidazo[1,2-a]pyridine-5-carboxylic acid ethylamide
 865605-31-8P, 1-[7-(2-Dimethylaminopyrimidin-5-yl)-5-(pyrimidin-2-yl)imidazo[1,2-a]pyridin-2-yl]-3-ethylurea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; preparation of imidazopyridines and imidazopyrimidines as antibacterials)

RN 865604-18-8 CAPLUS


CN Carbamic acid, [7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 865604-21-3 CAPLUS


CN Carbamic acid, [7-[2-(dimethylamino)-5-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)

10598841




RN 865604-22-4 CAPLUS

CN Urea, N-[7-[2-(dimethylamino)-5-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 865604-23-5 CAPLUS

CN Carbamic acid, [7-(6-methoxy-3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 865604-24-6 CAPLUS


CN Urea, N-ethyl-N'-[7-(6-methoxy-3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-
(CA INDEX NAME)



RN 865604-25-7 CAPLUS


CN Urea, N-ethyl-N'-[7-(2-methoxy-5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]-
(CA INDEX NAME)

10598841




RN 865604-28-0 CAPLUS

CN Urea, N-ethyl-N'-[7-[6-[2-(4-morpholinyl)ethoxy]-3-pyridinyl]imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)




RN 865604-36-0 CAPLUS

CN Urea, N-ethyl-N'-[5-(hydroxymethyl)-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865604-37-1 CAPLUS


CN Urea, N-ethyl-N'-[5-formyl-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865604-38-2 CAPLUS


CN Imidazo[1,2-a]pyridine-5-carboxylic acid, 2-[[(ethylamino)carbonyl]amino]-7-(3-pyridinyl)-, methyl ester (CA INDEX NAME)

10598841




RN 865604-50-8 CAPLUS

CN Urea, N-ethyl-N'-[7-(5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)




RN 865604-51-9 CAPLUS

CN Urea, N-[7-(3,5-dimethyl-4-isoxazolyl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 865604-52-0 CAPLUS


CN Urea, N-ethyl-N'-[7-[1-(phenylmethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865604-53-1 CAPLUS


CN Urea, N-ethyl-N'-[7-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)

10598841




RN 865604-54-2 CAPLUS

CN Urea, N-ethyl-N'-[7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl]-
(CA INDEX NAME)




RN 865604-55-3 CAPLUS

CN Urea, N-[7-(2,4-dimethoxy-5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]-N'-
ethyl- (9CI) (CA INDEX NAME)



RN 865604-57-5 CAPLUS


CN Urea, N-ethyl-N'-[7-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl]- (CA
INDEX NAME)



RN 865604-58-6 CAPLUS


CN Urea, N-[3-chloro-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl-
(CA INDEX NAME)

10598841




RN 865604-59-7 CAPLUS

CN Urea, N-[3-chloro-7-[2-(dimethylamino)-5-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (CA INDEX NAME)




RN 865604-65-5 CAPLUS

CN Urea, N-ethyl-N'-[7-(3-methyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865604-67-7 CAPLUS


CN Urea, N-[7-(1,5-dimethyl-1H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 865604-68-8 CAPLUS


CN Urea, N-[7-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)

10598841




RN 865604-69-9 CAPLUS

CN Urea, N-ethyl-N'-[7-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)




RN 865604-76-8 CAPLUS

CN Urea, N-ethyl-N'-[5-(1-methyl-1H-pyrazol-4-yl)-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865604-87-1 CAPLUS

CN Urea, N-[7-(3,5-dimethyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 865604-88-2 CAPLUS

CN Urea, N-ethyl-N'-[7-(1-piperidinylcarbonyl)imidazo[1,2-a]pyridin-2-yl]-


10598841

(CA INDEX NAME)




RN 865604-89-3 CAPLUS

CN Urea, N-cyclopropyl-N'-[7-(5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)




RN 865604-92-8 CAPLUS

CN Urea, N-(cyclopropylmethyl)-N'-[7-(5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865604-93-9 CAPLUS


CN Urea, N-propyl-N'-[7-(5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865604-94-0 CAPLUS


CN Urea, N-(1-methylethyl)-N'-[7-(5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)

10598841




RN 865604-96-2 CAPLUS

CN Urea, N-[7-(5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]-N'-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 865604-98-4 CAPLUS

CN Urea, N-(2-methoxyethyl)-N'-[7-(5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865604-99-5 CAPLUS


CN Urea, N-cyclobutyl-N'-[7-(5-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865605-00-1 CAPLUS


CN Urea, N-[7-(6-amino-3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (CA INDEX NAME)

10598841




RN 865605-01-2 CAPLUS

CN Urea, N-(7-acetylimidazo[1,2-a]pyridin-2-yl)-N'-ethyl- (CA INDEX NAME)




RN 865605-04-5 CAPLUS

CN Urea, N-ethyl-N'-[7-(5-methyl-1,3,4-oxadiazol-2-yl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865605-07-8 CAPLUS


CN Urea, N-ethyl-N'-[7-(1H-pyrazol-3-yl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)



RN 865605-11-4 CAPLUS


CN Urea, N-ethyl-N'-[7-(1,2,3-thiadiazol-4-yl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)

10598841




RN 865605-13-6 CAPLUS

CN Urea, N-ethyl-N'-[7-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)




RN 865605-16-9 CAPLUS

CN Urea, N-[7-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (CA INDEX NAME)



RN 865605-17-0 CAPLUS


CN Urea, N-[7-(2-amino-4-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (CA INDEX NAME)



RN 865605-18-1 CAPLUS


CN Urea, N-ethyl-N'-[7-(4-morpholinylcarbonyl)imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)

10598841




RN 865605-19-2 CAPLUS

CN Urea, N-ethyl-N'-[7-(2-methoxy-4-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-
(CA INDEX NAME)




RN 865605-20-5 CAPLUS

CN Urea, N-ethyl-N'-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-
(CA INDEX NAME)



RN 865605-21-6 CAPLUS


CN Urea, N-ethyl-N'-[7-(6-fluoro-3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-
(CA INDEX NAME)



RN 865605-22-7 CAPLUS


CN Urea, N-[7-(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl-
(CA INDEX NAME)

10598841




RN 865605-23-8 CAPLUS

CN Urea, N-ethyl-N'-[7-(6-methyl-3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-
(CA INDEX NAME)




RN 865605-24-9 CAPLUS

CN Urea, N-[7-(1,2-dihydro-1-methyl-2-oxo-4-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl-
(CA INDEX NAME)



RN 865605-25-0 CAPLUS


CN Imidazo[1,2-a]pyridine-5-carboxamide, 7-[2-(dimethylamino)-5-pyrimidinyl]-
N-ethyl-2-[[(ethylamino)carbonyl]amino]- (CA INDEX NAME)




RN 865605-31-8 CAPLUS

CN Urea, N-[7-[2-(dimethylamino)-5-pyrimidinyl]-5-(2-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)


10598841



IT 865604-49-5P 865604-66-6P 865604-83-7P
865604-84-8P 865604-85-9P 865605-43-2P
865605-44-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of imidazopyridines and imidazopyrimidines as
antibacterials)
RN 865604-49-5 CAPLUS
CN Urea, N-ethyl-N'-[7-(3-pyridinyl)-5-[[(tetrahydro-2H-pyran-2-
yl)oxy]methyl]imidazo[1,2-a]pyridin-2-yl]- (CA INDEX NAME)




RN 865604-66-6 CAPLUS
CN Imidazo[1,2-a]pyridine-7-carboxamide, N-[1-(dimethylamino)ethylidene]-2-
[[(ethylamino)carbonyl]amino]- (CA INDEX NAME)




RN 865604-83-7 CAPLUS
CN Carbamic acid, [5-chloro-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10598841




RN 865604-84-8 CAPLUS

CN Carbamic acid, [5-(1-methyl-1H-pyrazol-4-yl)-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 865604-85-9 CAPLUS

CN Imidazo[1,2-a]pyridin-2-amine, 5-(1-methyl-1H-pyrazol-4-yl)-7-(3-pyridinyl)- (CA INDEX NAME)




RN 865605-43-2 CAPLUS

CN Carbamic acid, [5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


CC1=CN(C(=O)OCC)C2=CN3C(=C(C=C3C=C2C4=CC=CC=C4N)C5=CC=CC=C5N5C(=N1)OC6=CC=CC=C6N5C)C

Imidazo[1,2-a]pyridin-2-amine, 5-(3-methyl-1,2,4-oxadiazol-5-yl)-7-(3-pyridinyl)- (CA INDEX NAME)





(preparation of imidazopyridines and imidazopyrimidines as antibacterials)

CN	Carbamic acid, [5-(aminocarbonyl)-7-(3-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
----	--



Page 34



AB Title compds. I [X1 = CH₂, NH, O; X2 = absent, NH, O, CH₂O, etc.; Y = N, CH, C-F, C-OMe; R1 = H, halo; R2 = cycloalkyl, hetero/aryl, heterocyclyl, etc.; R3 = H, cyclo/alkyl, NO₂, CONH₂ and derivs., hetero/aryl, etc.; R4 = alkyl, cyclopropyl, cyclobutyl, etc.; and their pharmaceutically acceptable salts] were prepared as antibacterial agents. For example, II was prepared in 2 steps by by Pd-cross coupling of 2-amino-4-bromopyridine with (pyridin-3-yl)boronic acid and cyclization with Et (2-chloroacetyl)carbamate. I showed inhibitory activity against *Neisseria gonorrhoeae*.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:457579 CAPLUS

DOCUMENT NUMBER: 144:170921

TITLE: Different directions of the reactions of
2-(acylamino)-3-chloroacrylonitriles with benzamidine
and 2-aminopyridineAUTHOR(S): Popil'nichenko, S. V.; Brovarets, V. S.; Chernega, O.
M.; Drach, B. S.CORPORATE SOURCE: Inst. Biorg. Khim. Naftokhim., NAN Ukr., Kiev, Ukraine
SOURCE: Dopovidi Natsional'noi Akademii Nauk Ukraini (2005),
(4), 128-133

CODEN: DNAUFL; ISSN: 1025-6415

PUBLISHER: Vidavnychii Dim "Akademperiodika"

DOCUMENT TYPE: Journal

LANGUAGE: Ukrainian


OTHER SOURCE(S): CASREACT 144:170921

IT 874668-53-8P



RL: SPN (Synthetic preparation); PREP (Preparation)
(heterocyclization reactions of (chlorocyanoethenyl)benzamides with
benzamidine and with 2-pyridinamines)

RN 874668-53-8 CAPLUS

CN Benzamide, N-(7-methylimidazo[1,2-a]pyridin-2-yl)- (CA INDEX NAME)



GI



AB ClCH:C(CN)NHCOC6H4R-4 (I; R = H, Me) reacted with benzamidine via
[2+3]cycloaddn. to give imidazoles (II), which underwent spirocyclization
with NaOH to give III. Cyclocondensation of I with 2-aminopyridines gave
N-imidazopyridinylbenzamides IV (R = H, Me; X = H, Me).

10598841

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:477237 CAPLUS

DOCUMENT NUMBER: 111:77237

ORIGINAL REFERENCE NO.: 111:13011a,13014a

TITLE: Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogs

AUTHOR(S): Kaminski, James J.; Puchalski, Chester; Solomon, Daniel M.; Rizvi, Razia K.; Conn, David J.; Elliott, Arthur J.; Lovey, Raymond G.; Guzik, Henry; Chiu, P. J. S.; et al.

CORPORATE SOURCE: Pharm. Res. Div., Schering Res., Bloomfield, NJ, 07003, USA

SOURCE: Journal of Medicinal Chemistry (1989), 32(8), 1686-700
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:77237


IT 121394-34-1 121394-35-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with bromobutanone)

RN 121394-34-1 CAPLUS

CN Imidazo[1,2-a]pyridin-2-amine, 7-(2-phenylethenyl)-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 121394-35-2 CAPLUS

CN Imidazo[1,2-a]pyridin-2-amine, 7-(2-phenylethenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI



AB Definition of the interrelationship between the conformational characteristics of a series of substituted imidazo[1,2-a]pyridines and their antiulcer activity was investigated by examining the conformational properties of imidazo[1,2-a]pyridine I [R = PhCH₂O, R₁ = H, R₂ = Me, R₃ = CH₂CN (II)], by using a variety of exptl. and theor. methods. The result of these studies was the identification of two distinctly different candidates, designated the folded and the extended conformation, resp., to represent the two possible min.-energy conformations of II. In order to select the biol. relevant conformer, a group of 3-substituted 2-methylimidazo[1,2-a]pyridines, having either a cis- or a trans-2-phenylethenyl substituent at the 8-position, were designed as conceptually simple and synthetically accessible semirigid analogs of the resp. candidate conformers. Gastric antisecretory activity was found to reside only in the trans isomers I (R = trans-PhCH:CH, R₁ = H, R₂ = Me; R₃ = Me, CH₂CN, NH₂), which mimic the extended conformation. This observation led to the construction of imidazo[1,2-a]pyrano[2,3-c]pyridine-3-acetonitrile (III), a rigid tricyclic analog that is effectively locked in the extended conformation and that exhibited an antiulcer profile comparable to that of prototype II. These results unequivocally demonstrate that, in accord with expectation for a drug operating at a specific receptor, the conformational characteristics of the mol. have a substantial effect in determining its antiulcer activity. More precisely, it has been demonstrated that it is the extended conformation of II that represents the bioactive form of the drug. These results constitute the basis for a mol. probe that should aid in the investigation of the as yet uncharacterized gastric proton pump enzyme (H⁺/K⁺-ATPase), by means of which II and its analogs presumably exert their pharmacol. actions.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:205064 CAPLUS

DOCUMENT NUMBER: 110:205064

ORIGINAL REFERENCE NO.: 110:33851a,33854a

TITLE: Tubulin-dependent hydrolysis of guanosine triphosphate as a screening test to identify new antitubulin compounds with potential as antimitotic agents: application to carbamates of aromatic amines

AUTHOR(S): Chi, Duanmu; Shahrik, Lilian K.; Ho, Holly H.; Hamel, Ernest

CORPORATE SOURCE: Lab. Biochem. Pharmacol., Natl. Cancer Inst., Bethesda, MD, 20892, USA

SOURCE: Cancer Research (1989), 49(6), 1344-8
CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 120602-09-7, NSC 311480

RL: BIOL (Biological study)

(antimitotic activity of, neoplasm inhibition from, structure in relation to)

RN 120602-09-7 CAPLUS

CN Carbamic acid, [7-(trichloroethenyl)imidazo[1,2-a]pyridin-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



AB Tubulin-dependent GTP hydrolysis was evaluated for its potential as a relatively simple screening assay for new antimitotic drugs. Carbamates of aromatic amines were chosen as the test system because of the relatively diverse structures of compds. in this class already known to have antimitotic properties and because of the large number of such compds. in the NSC collection of the National Cancer Institute. Of 162 compds. evaluated, alterations in the GTPase reaction were observed with 26 agents. Sixteen of these had substantial inhibitory effects on tubulin polymerization (true positives), while 10 did not (false positives). There were no false negatives (i.e., no agent inactive in the GTPase assay inhibited tubulin polymerization). The true positives were examined for effects on cell growth and

mitosis, and 4 compds. had 50% inhibitory concentration values of $\leq 2 \mu\text{M}$ with L1210- murine leukemia cells. All 4 caused the accumulation of cells in metaphase arrest. Thus, tubulin-dependent GTP hydrolysis can be used effectively to select new antitubulin compds. with potential as antimitotic agents from a large group of compds. of unknown activity.

10598841

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	27.73	217.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

STN INTERNATIONAL LOGOFF AT 15:33:27 ON 05 JUL 2008